IPH

Innate Pharma Announces Its Participation in Upcoming Investor Conference

Retrieved on: 
Tuesday, April 9, 2024
Communications, Health, General Health, Pharmaceutical, Public Relations, Investor Relations, Biotechnology, Euronext Paris, IPHA, IPH

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.

Key Points: 

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.

Neon One Unveils "The Recurring Giving Report: Data-Backed Insights for Sustainable Generosity" - Empowering Nonprofits with the Blueprint for Sustainable Revenue

Retrieved on: 
Monday, April 8, 2024
IPH, Research, Longevity, Content, Data analysis, Management

CHICAGO, April 8, 2024 /PRNewswire/ -- Neon One, the nonprofit platform made for building communities of generosity, today unveils a significant research initiative: "The Recurring Giving Report: Data-Backed Insights for Sustainable Generosity".

Key Points: 
  • CHICAGO, April 8, 2024 /PRNewswire/ -- Neon One, the nonprofit platform made for building communities of generosity, today unveils a significant research initiative: "The Recurring Giving Report: Data-Backed Insights for Sustainable Generosity".
  • The Recurring Giving Report showcases Neon One's dedication to operational growth in the nonprofit sector.
  • Analyzing data from 100,000+ recurring donors, it offers practical strategies for enhancing fundraising through recurring gifts.
  • Key Insights from the Report:
    Unprecedented Growth: Analysis reveals a 144% increase in recurring revenue among studied nonprofits over five years, with the average nonprofit's recurring donor base expanding by 127%.

Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F

Retrieved on: 
Friday, April 5, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Euronext Paris, Document, IPHA, IPH, Annual report

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2023 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2023 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 4, 2024.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2023 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2023 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 4, 2024.
  • It can be downloaded (in French) on the Company’s website and on the AMF’s website .
  • The Company also announced today the filing of its annual report on Form 20-F for the year ending December 31, 2023 with the United States Securities and Exchange Commission (“SEC”).
  • It can be also be accessed on the Company’s website and on the SEC’s website .

Innate Pharma Announces Its Participation to Upcoming Investor Conference

Retrieved on: 
Tuesday, March 19, 2024
Professional Services, Health, Finance, Research, Science, Pharmaceutical, Biotechnology, Euronext Paris, IPHA, IPH

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.
  • Participants will be Sonia Quaratino, Executive Vice President, Chief Medical Officer, Yannis Morel, Executive Vice President, Chief Operating Officer and Arvind Sood, Executive Vice President, President of US Operations.

Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Euronext Paris, Telephone, Webcast, IPHA, IPH, EDT

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2023.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2023.
  • Participants during the call will be:
    The live webcast will be available at the following link:
    Participants may also join via telephone using the following registration link: https://registrations.events/direct/Q4I409542
    This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com .
  • A replay of the webcast will be available on the Company website for 90 days following the event.

Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma

Retrieved on: 
Wednesday, March 6, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, CD20, IPH, CD16, NHL, NCR1, Relapse, IPHA, Safety, Therapy, Patient, NK, Euronext Paris, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1/2 multicenter trial ( NCT06088654 ), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma (NHL).

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1/2 multicenter trial ( NCT06088654 ), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma (NHL).
  • The study is planned to enroll up to 184 patients.
  • “We are pleased to announce the dosing of a first patient in this Phase 1/2 study evaluating IPH6501, our proprietary ANKET® asset and the first tetraspecific NK Cell Engager to enter the clinic.” commented Dr Sonia Quaratino, Chief Medical Officer at Innate Pharma.
  • In this context, IPH6501 represents an innovative option for the treatment of patients with R/R B-cell non-Hodgkin’s lymphomas and has the potential to fulfil a large unmet need.”

Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Euronext Paris, IPH, Neoplasm, Engineering, Doctor of Philosophy, AACR, IPHA, DVM, ADC

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.
  • "We are excited to present our findings on IPH45 at this year's AACR.
  • Our studies demonstrate that IPH45 effectively inhibits tumor growth both in vitro and in vivo, and it exhibits a favorable safety profile in preclinical studies," stated Prof. Eric Vivier, DVM, PhD, Chief Scientific Officer at Innate Pharma.
  • "These promising results underscore the potential of IPH45 and reflect our dedication to pioneering the next wave of cancer treatments through advanced antibody engineering.

Innate Pharma Announces Its Participation to Upcoming Investor Conference

Retrieved on: 
Wednesday, February 21, 2024
Professional Services, Oncology, Health, Finance, Pharmaceutical, Biotechnology, IPHA, Euronext Paris, IPH

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the upcoming investor conference, detailed below.

Key Points: 

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the upcoming investor conference, detailed below.

International forum highlights the transformative power of lifestyle medicine to treat chronic disease and redefine health care

Retrieved on: 
Wednesday, February 28, 2024
Education, Death, Society, Non-communicable disease, CHES, American College, The Institute, Certification, WHO, IPH, Notifiable disease, International Board, Pharmacist, FACPM, Physician, Dentist, Weill Cornell Medicine, ACLM, CHWC, United Nations, Nursing, MPH, Knowledge, UN, LMGA, Human, Master of Science, United, CWP, Population health, Cancer, Public health, World Health Organization, Medicine, Pharmaceutical industry

ST. LOUIS, Feb. 28, 2024 /PRNewswire-PRWeb/ -- More than two dozen international experts in lifestyle medicine from 21 countries converged recently in Qatar at a forum to advocate for the growing medical specialty as an effective approach to treating noncommunicable chronic disease and transforming health worldwide.

Key Points: 
  • The Feb. 17 event, "Lifestyle Medicine - Redefining Healthcare to Promote Wellbeing," was organized by The Institute for Population Health (IPH) of Weill Cornell Medicine-Qatar, the Lifestyle Medicine Global Alliance (LMGA), and the International Board of Lifestyle Medicine (IBLM).
  • The forum was designed for physicians and other health professionals, including nurses, public health professionals, dentists, pharmacists, health care administrators, researchers and educators to develop the knowledge to discuss the growing field of lifestyle medicine and its opportunities, advancement and challenges.
  • Since certification in lifestyle medicine began in 2017, nearly 6,700 physicians and other health professionals have earned certification globally.
  • Ravinder Mamtani, MD, MSc, FACPM, FACOEM, DipABLM, vice dean for Population Health and Lifestyle Medicine, Weill Cornell Medicine – Qatar, and Sivaneswaran Poobalasingam, MD, DipIBLM, president of the Malaysian Society of Lifestyle Medicine, said the forum reinforced their belief that lifestyle medicine is "the way forward" for health care.

Independence Pet Holdings Names Sharon Fernandez Chief Executive Officer

Retrieved on: 
Tuesday, February 13, 2024
IPH, Pet, Farmers Insurance Group, Farmer, Insurance, USAA, Omnichannel, Corporation, Management

SCOTTSDALE, Ariz., Feb. 13, 2024 /PRNewswire/ -- Independence Pet Holdings ("IPH"), one of North America's leading pet insurance organizations, today announced the appointment of Sharon Fernandez as Chief Executive Officer, effective immediately.

Key Points: 
  • SCOTTSDALE, Ariz., Feb. 13, 2024 /PRNewswire/ -- Independence Pet Holdings ("IPH"), one of North America's leading pet insurance organizations, today announced the appointment of Sharon Fernandez as Chief Executive Officer, effective immediately.
  • IPH is an affiliate of JAB Pet Holdings, a leading global pet insurance organization, and the parent company of Independence Pet Group, Embrace and Pumpkin.
  • In addition, IPH owns PetPlace, a diverse portfolio of pet health and wellness services including pet adoption solutions and lost pet recovery services.
  • "I'm excited to announce the appointment of Sharon, which helps further our mission of building a better future for pets and pet parents," said Dirk Beeckman, CEO of JAB Pet Holdings.